Luca Vittorio Carlo Valenti, Doctor

CONTACT

Lead Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Yes

•Patients with advanced MASLD defined as liver fibrosis ≥2 and/or the development of HCC (Hepatocellular Carcinoma);
•Patients enrolled in the context of the SERENA study and, where applicable, also in the context of the REASON study;
•Liver biopsy for suspected Non-Alcoholic Steatohepatitis (NASH) at the time of diagnosis;
•Cholecystectomies;
•Age \[40-70 years\];
•Patients who have signed the informed consent form.
•Blood donors participating in the Liver Bible study aged between 40 and 70 years who are overweight or obese and have at least two of the following risk factors:
•Impaired fasting glucose or Diabetes Mellitus
•Dyslipidemia
•Arterial hypertension.

•Positivity for chronic viral hepatitis (HCV-RNA and/or HBsAg);
•Positivity for other liver diseases such as autoimmune and viral hepatitis (Hepatitis B and C), hereditary hemochromatosis, alpha-1-antitrypsin deficiency, or Wilson's disease.
•Subjects with chronic degenerative diseases will be excluded, with the exception of well-controlled hypertension and Type 2 Diabetes Mellitus that does not require pharmacological therapy (as is already standard practice for blood donation eligibility). Also excluded are donors aged \> 65 and \< 40 years.

Related studies

NCT07552727 · Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)

NCT06345547 · Sarcopenia, Cirrhosis, and more

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

NCT07439939 · Liver Cirrhosis, Portal Hypertension

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD